Kidney Transplant Rejection Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alphamab Oncology, AltruBio Inc, Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squ

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Kidney Transplant Rejection pipeline constitutes 15+ key companies continuously working towards developing 15+ Kidney Transplant Rejection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Kidney Transplant Rejection Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Kidney Transplant Rejection Market.

The Kidney Transplant Rejection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Kidney Transplant Rejection Pipeline Report: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Kidney Transplant Rejection treatment therapies with a considerable amount of success over the years.
• Kidney Transplant Rejection companies working in the treatment market are Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Inc., Sangamo Therapeutics, Horizon Therapeutics Plc, CSL Behring, Medeor Therapeutics, Inc., and others, are developing therapies for the Kidney Transplant Rejection treatment
• Emerging Kidney Transplant Rejection therapies in the different phases of clinical trials are- VEL-101, Tegoprubart, TX200, Dazodalibep, Clazakizumab, MDR-101, and others are expected to have a significant impact on the Kidney Transplant Rejection market in the coming years.
• In July 2023, Clarava, a pre-transplant prognostic test to measure a patient's immune response and assess the risk of early kidney transplant rejection, has successfully completed its prospective, blinded, clinical validation study, according to Verici Dx, a developer of clinical diagnostics for organ transplant.
• In July 2023, The Australian Therapeutic Goods Administration ("TGA") has provisionally approved Idefirix (imlifidase) as a desensitisation treatment for highly sensitised patients prior to kidney transplantation from both living and deceased donors, according to Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions. The two-year provisional clearance was based on results from Hansa's phase 2 studies1-4, which comprised highly sensitive patients who got kidney transplants from either living (17%) or deceased (83%) donors after receiving imlifidase desensitisation therapy.

Kidney Transplant Rejection Overview
Kidney transplant rejection is an allogeneic immune reaction that degrades the graft's function and causes graft destruction. Patients who do not take their medicine as directed or who have insufficient immunosuppression frequently experience it.

Get a Free Sample PDF Report to know more about Kidney Transplant Rejection Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Kidney Transplant Rejection Drugs Under Different Phases of Clinical Development Include:
• VEL-101: Veloxis Pharmaceuticals, Inc.
• Tegoprubart: Eledon Pharmaceuticals, Inc.
• TX200: Sangamo Therapeutics
• Dazodalibep: Horizon Therapeutics Plc
• Clazakizumab: CSL Behring
• MDR-101: Medeor Therapeutics, Inc.

Kidney Transplant Rejection Route of Administration
Kidney Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Kidney Transplant Rejection Molecule Type
Kidney Transplant Rejection Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Kidney Transplant Rejection Pipeline Therapeutics Assessment
• Kidney Transplant Rejection Assessment by Product Type
• Kidney Transplant Rejection By Stage and Product Type
• Kidney Transplant Rejection Assessment by Route of Administration
• Kidney Transplant Rejection By Stage and Route of Administration
• Kidney Transplant Rejection Assessment by Molecule Type
• Kidney Transplant Rejection by Stage and Molecule Type

DelveInsight's Kidney Transplant Rejection Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Kidney Transplant Rejection product details are provided in the report. Download the Kidney Transplant Rejection pipeline report to learn more about the emerging Kidney Transplant Rejection therapies at:
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Kidney Transplant Rejection Therapeutics Market include:
Key companies developing therapies for Kidney Transplant Rejection are - Alphamab Oncology, AltruBio Inc, Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others.

Kidney Transplant Rejection Pipeline Analysis:
The Kidney Transplant Rejection pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Kidney Transplant Rejection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Kidney Transplant Rejection Treatment.
• Kidney Transplant Rejection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Kidney Transplant Rejection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Kidney Transplant Rejection market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Kidney Transplant Rejection drugs and therapies-
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Kidney Transplant Rejection Pipeline Market Drivers
• Rising Prevalence of chronic kidney diseases, increasing Number of Kidney Transplantations are some of the important factors that are fueling the Kidney Transplant Rejection Market.

Kidney Transplant Rejection Pipeline Market Barriers
• However, lack of donor and knowledge, long waiting time for transplantation and other factors are creating obstacles in the Kidney Transplant Rejection Market growth.

Scope of Kidney Transplant Rejection Pipeline Drug Insight
• Coverage: Global
• Key Kidney Transplant Rejection Companies: VEL-101, Tegoprubart, TX200, Dazodalibep, Clazakizumab, MDR-101, and others
• Key Kidney Transplant Rejection Therapies: Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Inc., Sangamo Therapeutics, Horizon Therapeutics Plc, CSL Behring, Medeor Therapeutics, Inc., and others
• Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection current marketed and Kidney Transplant Rejection emerging therapies
• Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers

Request for Sample PDF Report for Kidney Transplant Rejection Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Kidney Transplant Rejection Report Introduction
2. Kidney Transplant Rejection Executive Summary
3. Kidney Transplant Rejection Overview
4. Kidney Transplant Rejection- Analytical Perspective In-depth Commercial Assessment
5. Kidney Transplant Rejection Pipeline Therapeutics
6. Kidney Transplant Rejection Late Stage Products (Phase II/III)
7. Kidney Transplant Rejection Mid Stage Products (Phase II)
8. Kidney Transplant Rejection Early Stage Products (Phase I)
9. Kidney Transplant Rejection Preclinical Stage Products
10. Kidney Transplant Rejection Therapeutics Assessment
11. Kidney Transplant Rejection Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Kidney Transplant Rejection Key Companies
14. Kidney Transplant Rejection Key Products
15. Kidney Transplant Rejection Unmet Needs
16 . Kidney Transplant Rejection Market Drivers and Barriers
17. Kidney Transplant Rejection Future Perspectives and Conclusion
18. Kidney Transplant Rejection Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Kidney Transplant Rejection Market https://www.delveinsight.com/report-store/kidney-transplant-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Kidney Transplant Rejection-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Kidney Transplant Rejection Epidemiology https://www.delveinsight.com/report-store/kidney-transplant-rejection-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Kidney Transplant Rejection Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.